107 [89Zr]Zr-DFO-durvalumab PET/CT before durvalumab treatment in R/M SCCHN patients A B Figure S7. Kaplan-Meier estimates of progression free survival based on [18F]FDG SUVpeak (A) and total lesion glycolysis dichotomized at median value, after correcting for lesions <20mm. 5
RkJQdWJsaXNoZXIy MTk4NDMw